Recurrence-free survival | Overall survival | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||||||||
HR | 95% CI | p | HR | 95% CI | p | HR | 95% CI | p | HR | 95% CI | p | |
Sex | ||||||||||||
Male | 1.70 | 0.77–3.74 | 0.19 | 1.23 | 0.33–4.64 | 0.76 | ||||||
Female | 1 | 1 | ||||||||||
Age (years) | ||||||||||||
< 65 | 1 | 1 | ||||||||||
≥ 65 | 0.95 | 0.42–2.18 | 0.91 | 1.46 | 0.39–5.49 | 0.58 | ||||||
AV distance (cm) | ||||||||||||
< 5 | 1.29 | 0.64–2.58 | 0.48 | 1.69 | 0.45–6.39 | 0.44 | ||||||
≥ 5 | 1 | 1 | ||||||||||
CEA level (ng/mL) | ||||||||||||
< 5 | 1 | 1 | ||||||||||
≥ 5 | 1.80 | 0.93–3.53 | 0.84 | 1.16 | 0.34–3.97 | 0.81 | ||||||
cT stage | ||||||||||||
T2 and T3 | 1 | 1 | 1 | |||||||||
T4 | 3.00 | 1.53–5.91 | 0.001 | 2.01 | 0.92–4.42 | 0.08 | 3.24 | 0.99–10.62 | 0.05 | |||
cN stage | ||||||||||||
Negative | 1 | 1 | ||||||||||
Positive | 1.35 | 0.69–2.62 | 0.38 | 0.87 | 0.27–2.85 | 0.82 | ||||||
Clinical LPLN metastasis | ||||||||||||
Negative | 1 | 1 | ||||||||||
Positive | 1.71 | 0.84–3.48 | 0.14 | 1.38 | 0.37–5.21 | 0.64 | ||||||
Clinical CRM | ||||||||||||
Negative | 1 | 1 | 1 | 1 | ||||||||
Positive | 2.99 | 1.54–5.80 | 0.001 | 1.97 | 0.90–4.35 | 0.09 | 4.43 | 1.30–15.14 | 0.02 | 3.24 | 0.90–11.68 | 0.07 |
ymrEMVI | ||||||||||||
Negative | 1 | 1 | 1 | 1 | ||||||||
Positive | 3.37 | 1.72–6.61 | < 0.001 | 2.74 | 1.36–5.50 | 0.005 | 4.43 | 1.35–14.51 | 0.01 | 3.15 | 0.91–10.89 | 0.07 |
TVRR (%) | ||||||||||||
< 60 | 3.37 | 1.53–7.42 | 0.003 | 3.48 | 1.57–7.72 | 0.002 | 3.90 | 0.84–18.06 | 0.08 | |||
≥ 60 | 1 | 1 | 1 |